Sclerostin levels decreased while DKK1 concentrations increased after ATD treatment and euthyroid state achievement, accompanied by improvements in the lumbar spine, hip bone density, biomarkers of bone remodeling OC, β-CTX, and DPD. This evidence concerns the gene SOST and Jeune syndrome.